The FDA issues a decision on the drug candidate with a target date of October 9, 2026.

Question

Six frontier AI models put this at 87% by 31 Oct 2026. Full reasoning from every model.

WillHappen.ai · Accepted Answer

87% — the median of 6 frontier models, resolving by 2026-10-31.

Answer

Gemini (Google): 88% — PDUFA goal dates are met on or before schedule roughly 90% of the time unless a major amendment triggers a standard 3-month extension. FDA historical performance reports show CDER and CBER meet over 88% of PDUFA action dates on or before the statutory goal. The primary risk of delay is a late submission of substantial data triggering a standard three-month review clock extension. A formal extension notice issued prior to October 9 would be the single factor reducing this probability to zero.

Answer

Claude (Anthropic): 78% — Hinges on whether FDA meets its own PDUFA deadline, which it does most of the time historically. FDA historically meets PDUFA target dates roughly 85-90% of the time, with occasional short delays. No specific red flags mentioned in context about this candidate suggesting manufacturing or data issues causing delay. A late-stage inspection problem or requested additional data could push the decision past Oct 9, which would resolve this negatively if truly on that exact date.

Answer

GPT (OpenAI): 87% — This chiefly turns on whether the Oct. 9 date is a formal PDUFA action date rather than an estimated calendar entry. For standard NDAs and BLAs, FDA usually acts by the PDUFA goal date; an Oct. 9 action leaves only eight days. The main ways this slips are a late major amendment, an unexpected manufacturing issue, or a complete-response delay. A public FDA extension notice, or confirmation that Oct. 9 is merely projected, would materially lower the odds.

Answer

Grok (xAI): 82% — FDA action on the Oct 9 PDUFA goal without an announced delay. CDER/CBER must complete review and issue approval or CRL by the statutory goal date of Oct 9. No delay or major-amendment clock extension has been posted with eight days remaining, matching the ~80-90% historical on-time rate. A late complete-response letter or internal hold would drop the odds; none is visible now.

Answer

DeepSeek (DeepSeek): 92% — PDUFA dates are met ~90%+ of the time; the question is whether this one slips or gets pulled. The FDA acts on the sponsor's PDUFA date in the large majority of cases; a 2024 analysis of novel drugs found roughly 90% of action dates hit within the target month. Only the FDA's review division must act, and the Oct. 9 date is already the agency's own committed deadline, so no external body needs to clear anything first. The main risk is a three-month extension for a major amendment or a complete response letter arriving late, which would push the announcement past Oct. 31.

Answer

Qwen (Alibaba): 87% — FDA meets PDUFA dates ~93% of the time; the question is whether this specific drug's review is on track. FDA historically acts on ~93% of PDUFA dates on time; delays typically stem from late manufacturing issues or advisory committee needs. The statement says 'a decision' without naming the drug, so it resolves on whichever candidate carries the Oct. 9 date—any single NDA/BLA with that target suffices. A development that would drop this below 70% is a publicly announced delay or a complete response letter issued early, which would still count as a decision.

The FDA issues a decision on the drug candidate with a target date of October 9, 2026.

An FDA-approved treatment that reverses or fully halts cognitive decline in Alzheimer's disease becomes available before 2035.

A curative treatment for at least three of the top five deadliest cancers is approved by the FDA before October 2036.

A universal cure or vaccine effectively eliminating cancer mortality across most major types is approved by regulatory agencies before 2040.

The World Health Organization explicitly characterizes a Hantavirus outbreak as a pandemic in 2026.